Company’s 36-month beta value is 0.38.Analysts have differing opinions on the stock, with 17 analysts rating it as a “buy,” 10 as “overweight,” 11 as “hold,” and 2 as “sell.”
The public float for VRTX is 256.86M, and currently, short sellers hold a 1.75% ratio of that floaft. The average trading volume of VRTX on November 15, 2024 was 1.06M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VRTX) stock’s latest price update
Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) has seen a decline in its stock price by -2.15 in relation to its previous close of 494.61. However, the company has experienced a -3.68% decline in its stock price over the last five trading sessions. fool.com reported 2024-11-13 that Regulators are reviewing what could become a multi-billion-dollar drug.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc (VRTX) has seen a -3.68% fall in stock performance for the week, with a -0.68% decline in the past month and a 1.38% surge in the past quarter. The volatility ratio for the week is 2.92%, and the volatility levels for the past 30 days are at 2.58% for VRTX. The simple moving average for the past 20 days is -0.01% for VRTX’s stock, with a 6.74% simple moving average for the past 200 days.
VRTX Trading at 1.58% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.91% of loss for the given period.
Volatility was left at 2.58%, however, over the last 30 days, the volatility rate increased by 2.92%, as shares sank -2.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.28% upper at present.
During the last 5 trading sessions, VRTX fell by -3.68%, which changed the moving average for the period of 200-days by +11.67% in comparison to the 20-day moving average, which settled at $484.02. In addition, Vertex Pharmaceuticals, Inc saw 18.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from WAGNER CHARLES F JR, who sale 3,000 shares at the price of $518.27 back on Nov 11 ’24. After this action, WAGNER CHARLES F JR now owns 44,137 shares of Vertex Pharmaceuticals, Inc, valued at $1,554,810 using the latest closing price.
Kewalramani Reshma, the CEO & President of Vertex Pharmaceuticals, Inc, sale 15,198 shares at $515.00 during a trade that took place back on Nov 08 ’24, which means that Kewalramani Reshma is holding 75,772 shares at $7,826,970 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -2.99, with -2.18 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -0.49. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -8.18.
Currently, EBITDA for the company is 4.61 billion with net debt to EBITDA at -6.83. When we switch over and look at the enterprise to sales, we see a ratio of 11.41. The receivables turnover for the company is 6.06for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.47.
Conclusion
In a nutshell, Vertex Pharmaceuticals, Inc (VRTX) has experienced a mixed performance in recent times. The stock has received mixed “sell” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
